WHO Strategy Could End Cervical Cancer Tops SPT Week in Review

5. How Immunotherapy is Changing the Treatment of Small Cell Lung Cancer

Meaningful improvements in outcomes with immunotherapy in recent years are finally starting to change the tide for the first-line treatment of patients with small-cell lung cancer. Read more.

4. Phase 3 Trial Demonstrates Positive Results for Enzalutamide in Prostate Cancer

Positive results were based on the PROSPER trial, which evaluated the overall survival of enzalutamide plus androgen deprivation therapy versus standard of care. Read more.

3. Niraparib Found to Improve Progression-Free Survival in Women with Advanced Ovarian Cancer

Treatment with niraparib resulted in a 38% reduction in the risk of disease progression or death in the overall study population compared with placebo. Read more.

2. Merck Selling Older, Slower Growth Products Through New Pharmaceutical Company

Merck has announced its plan to spin-off products from its women's health, trusted legacy brands, and biosimilars into a new, independent, and publicly traded corporation. Read more.

1. New Studies Point to Efficacy of WHO Three-Part Strategy to End Cervical Cancer

Two studies published in The Lancet have developed models to examine what may happen if the World Health Organization commits to a 3-part strategy to end cervical cancer. Read more.

As a pharmacist, your insight has a direct effect on patient outcomes. Help drive medicine forward with your opinions. Participate in a quick survey of OTC products for a chance to win a $1,000 Visa gift card. Vote now by clicking here: https://hraresearchnetwork.com/wix/p6499706.aspx?hPTsource=5